neurodegenerative disease

(redirected from CNS Disorder)

neurodegenerative disease

Any of a group of hereditary and sporadic conditions characterised by progressive dysfunction, degeneration and death of specific populations of neurones which are often synaptically interconnected.

Neurodegenerative diseases
Akinetic-rigid
Examples
Parkinson’s disease, progressive supranuclear palsy, corticobasal degeneration, multisystem atrophy with striatonigral degeneration.

Clinical findings
Bradykinesia, rigidity.

Location
Substantia nigra, basal ganglia.

Hyperkinetic
Examples
Huntington’s disease, dentatorubropallidoluysial atrophy.

Clinical findings
Choreoathetosis, dystonia.

Location
Basal ganglia.

Ataxic
Examples
Friedrich’s ataxia, spinocerebellar degeneration, dentatorubropallidoluysial atrophy.

Clinical findings
Cerebellar ataxia.

Location
Cerebellum and connecting tracts.

Motor neuron disease
Examples
Amyotrophic lateral sclerosis, spinobulbar muscle atrophy (Kennedy’s disease), spinal muscular atrophy.

Clinical findings
Motor weakness.

Location
Motor system.

Temporoparietal degeneration
Examples
Alzheimer’s disease, dementia with Lewy bodies.

Clinical findings
Memory changes, parietal lobe dysfunction.

Location
Hippocampus, cortical neurons.

Frontotemporal degeneration
Example
Frontotemporal lobar degeneration.

Clinical findings
Apathy, disinhibition, memory changes.

Location
Frontal and temporal cortex.

Multifocal degeneration
Example
Prion disease.

Clinical findings
Variable cortical and subcortical changes.

Location
Cortical, subcortical neurons.

Neurodegenerative disease

A disease in which the nervous system progressively and irreversibly deteriorates.
Mentioned in: Amnesia
References in periodicals archive ?
184), to infer that the Lyme-causing bacterium led to a CNS disorder, Halperin says.
Some of these novel emerging drug classes for CNS disorder treatment are analyzed in our report.
GBI Research, the leading business intelligence provider, has released its latest research Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010, which provides insights into CNS disorder therapeutics market until 2017.
The CNS disorder clinical trial research report combines detailed commentary with a large number of charts and tables to provide the reader with a comprehensive overview of the market.
It is developing its next generation modulators, including SAGE-217 and SAGE-718, with a focus on acute and chronic CNS disorders.
The topics include magnetic resonance imaging as a tools for modeling drug treatment of CNS disorders, small animal imaging as a tool for modeling CNS disorders, positron emission tomography in Alzheimer disease, neuroimaging as a translational tool in animal and human models of schizophrenia, translational neuroimaging for drug discovery and development in autism spectrum disorders, and neuroimaging approaches to understanding depression and identifying novel antidepressants.
BioFocus, the Galapagos' service division, and Ono Pharmaceutical announced that it has inked a new drug discovery agreement, which focuses on CNS disorders.
BR) announced today that its service division BioFocus and Ono Pharmaceutical Co Ltd, a Japanese drug discovery company, have signed a new collaboration agreement, focused on discovering novel drugs in the field of CNS disorders.
NORDIC BUSINESS REPORT-October 15, 2010--Biotie to regain rights to CNS disorders drug candidate(C)2010 M2 COMMUNICATIONS http://www.
Depression and schizophrenia had the largest number of trials among CNS disorders, but the number of early-phase trials for each decreased, while the number of earlier stage trials for Alzheimer's disease, multiple sclerosis, sleep disorders and attention-deficit/hyperactivity disorder increased.
com/research/mv3bdf/global_cns) has announced the addition of the "Global CNS Disorders Drug Pipeline Capsule - 2012" report to their offering.
Osaka Japan) have signed a new collaboration agreement, focused on discovering novel drugs in the field of CNS disorders.